(NewsDirect)
Emyria Ltd (ASX:EMD)MD Michael Winlo talks Proactive through the highlights of its Junequarter. The company initiated the acquisition of the Pax Centre,extending its reach in the mental health space.
EMD received HumanResearch Ethics Committee approval to commence EMDMA-001, a novelMDMA-assisted therapy trial for PTSD. Also, at the start of theperiod, Emyria signed an exclusive licensing and commercialisationterm sheet with Aspen Pharmacare Australia, securing a major partnerto support the registration and commercialisation of the prospectiveEMD-RX5 treatment for mild anxiety and stress.
Winlo said in thecompany’s quarterly statement: “Emyria’s acquisition of The PaxCentre this quarter is a substantial extension of our capabilities andexpertise in mental health.
“By integrating the Pax Centre with EmeraldClinics we aim to create a thriving, multidisciplinary clinicalservice that generates growing revenues while capturing robustclinical data to support our ongoing cannabinoid and MDMA-inspiredmedicine development programs.
“Webelieve the unique “wraparound” care model we are building offersadvantages over alternative models for delivering promising emerginginterventions like MDMA and psilocybin-assisted therapy and that thedata we are gathering can help advance the development andregistration of treatments with potential to help large patientpopulations.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.